Summit falls despite phase 3 ivonescimab data in NSCLC
Source: SeekingAlpha
2026-06-01 17:12:30 ET
More on Summit Therapeutics
- Summit Therapeutics Inc. (SMMT) Discusses Plenary Session Updates and Recent Clinical Data Following Major Oncology Congress Transcript
- Summit Therapeutics: More Uncertainty Heading Into The ASCO Plenary
- Summit Therapeutics: It Still Feels Like The Market Got Ahead Of Itself
- Summit downgraded at H.C. Wainwright after Merck data for sac-TMT
- Summit Therapeutics falls after update on Akeso-partnered lung cancer trial
Read the full article on Seeking Alpha
For further details see:
Summit falls despite phase 3 ivonescimab data in NSCLC
Summit Therapeutics Inc.
NASDAQ: SMMT
SMMT Trading
-2.55% G/L:
$14.53 Last:
2,046,527 Volume:
$14.925 Open:
SMMT Latest News
May 31, 2026 02:05:00 pm
This Emerging Risk Is Unlike Anything the Biotech Industry Has Ever Experienced
SMMT Stock Data
$11,408,581,895
112,410,823
0.02%
74
N/A
Biotechnology & Life Sciences
Healthcare
US
Miami
